Arnon Rosenthal PhD

Rosenthal received his Ph.D. From the Hebrew University of Jerusalem, Israel. He was appointed to a scientist at Genentech Inc. In 1988, was promoted to a senior scientist in 1992, and then to a VP level, executive staff scientist, and a permanent member of Genentech Research Review Committee in 1996 where he Initiated the research program that led to the development and approval of Erivedge® (vismodegib)‎. In 2001 Dr. Rosenthal co-founded and became the president, board member, and CSO of Rinat Neuroscience, a privately held company that discovered novel medicines for neurodegenerative, and pain disorders. The company was acquired by Pfizer in 2006 for ~$500M with several clinical drugs including Tanezumab; Phase III for multiple pain indications, AJOVY® (fremanezumab-vfrm) approved for migraine, Bococizumab approved for cardiovascular disorders, RN6G; Phase II for dry macular degeneration; Ponezumab; Phase II for Alzheimer’s disease. Rosenthal is a co-founder, former CEO, and board chair of Annexon bio. Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. Dr, Rosenthal is a co-founder president, and current CEO of Alector, a public Biotechnology company (NASDAQ: ALEC) focused on the discovery and envelopment of novel microglia immune checkpoint therapy for Alzheimer's disease and other forms of dementia. Http://alector.com Rosenthal was a visiting professor at the Department of Anatomy UCSF and is a member of the scientific advisory boards of Simons Foundation Autism Research and of the Myelin Repair Foundation. He has co-authored over 100 scientific publications, and over 380 issued patents and applications. Https://en.m.wikipedia.org/wiki/Arnon_Rosenthal